Drug intelligence / Profile preview

beta-amyrin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Beta-amyrin is a naturally occurring pentacyclic triterpenoid compound found in various medicinal plants, including *Protium heptaphyllum*, *Alstonia scholaris*, and *Catharanthus roseus*. It is primarily investigated as a research compound for its broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and neuroprotective effects. Mechanistically, beta-amyrin has been shown to inhibit acetylcholinesterase (AChE) activity and modulate intracellular signaling pathways such as ERK1/2 and GSK-3β, which may contribute to its ability to attenuate cognitive impairment in models of Alzheimer's disease. Additionally, it acts as an agonist for cannabinoid receptors CB1 and CB2 and can modulate Bax-mediated apoptotic pathways. While it has demonstrated efficacy in various animal models for conditions like hepatic fibrosis, atherosclerosis, and tuberculosis, it is not currently developed as a commercial pharmaceutical product by any specific company and remains in the preclinical research stage.

Other names
β-amyrinolean-12-en-3beta-ololean12-en-3beta-ololean 12-en-3beta-ol12-oleanen-3-beta-ol
02

Targets

MGLL (Monoacylglycerol lipase)CNR1 (Cannabinoid receptor 1)AcetylcholinesteraseMAPK3 (Mitogen-activated protein kinase 1)GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on beta-amyrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-amyrin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call